Micafungina Teva

Micafungin, the active ingredient in Micafungina Teva, is an echinocandin presented as an injection for intravenous use. It treats invasive fungal infections such as candidemia, esophageal candidiasis and provides prophylaxis against aspergillosis in immunocompromised patients.

GNH USA supplies Micafungina Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches for global distribution. Clients benefit from reliable logistics, cold‑chain management and comprehensive documentation to meet import requirements.

Micafungin is used to treat and prevent invasive fungal infections by targeting the cell wall of susceptible Candida and Aspergillus species.

Invasive candidiasis: effective treatment of bloodstream and deep‑tissue Candida infections in adult and pediatric patients. Candida esophagitis: promotes healing of esophageal infection caused by Candida species. Febrile neutropenia: used as empirical therapy for fever in neutropenic patients at risk of invasive fungal disease. Prophylaxis of invasive aspergillosis: administered to high‑risk patients to prevent Aspergillus infection.

Micafungin may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Fever - Nausea - Elevated liver enzymes (ALT, AST)

Serious or Rare Side Effects: - Severe hepatic failure - Anaphylactic or severe hypersensitivity reactions - Stevens‑Johnson syndrome or toxic epidermal necrolysis

When using Micafungina Teva, clinicians should observe several safety considerations to minimize risk.

- Monitor liver function: assess ALT/AST levels before and during therapy. - Assess renal function: evaluate serum creatinine and adjust if impairment present. - Use caution in patients with known hypersensitivity to echinocandins. - Avoid use in severe hepatic impairment unless benefits outweigh risks. - Review concomitant medications for potential interactions. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin can interact with other medicines; some combinations require avoidance while others need close monitoring.

Major Interactions (Avoid): - Rifampin or other strong CYP3A4 inducers: may markedly reduce micafungin exposure. - Co‑administration with other echinocandins: provides no added benefit and increases toxicity risk.

Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., fluconazole, voriconazole): may increase micafungin plasma levels. - Immunosuppressants (e.g., tacrolimus, cyclosporine): monitor drug concentrations. - Warfarin: observe INR for possible alteration. - Statins (e.g., simvastatin): watch for signs of myopathy.